Skip to content

Study for Antiviral Therapy of Patients Co-infected with HIV and HCV

Study for Antiviral Therapy of Patients Co-infected with HIV and HCV

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020246
Enrollment
Unknown
Registered
2018-12-21
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/HCV Co infactiong

Interventions

1:Epclusa@(Sofosbuvir/ velpatasvir)(po)
1:Genvoya@(elvitegravir 150mg/cobicistat150mg/emtricitabine200mg/tenofovir alafenamide10mg)(po)

Sponsors

Guangzhou Eighth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 65 years; 2. weight more than 35 kg (no exclusion based on sex); 3. HIV-antibodies tested positive at least six months ago; HCV treatment-exposed patients must have undetectable HIV RNA within the past 12 months; 4. anti-HCV antibody or HCV RNA tested positive at least six months ago, and has tested positive for HCV RNA positive within six months of recruitment; HCV treatment-exposed patients who took PR regimen have to provide quantitative and qualitative HCR RNA test results in the period prior to treatment, 12 weeks after receiving treatment, upon termination of treatment, and 24 weeks after termination of treatment (excluding those who terminated treatment due to adverse drug reactions); 5. voluntarily agreed to sign the informed consent, participate in the study, and be able to cooperate with us for the follow-up.

Exclusion criteria

Exclusion criteria: 1. acute HIV or HCV infection at the time of recruitment; 2. opportunistic infections (according to the National AIDS Treatment Guidelines) or AIDS-related malignancy at the time of recruitment; has had opportunistic infections within 3 months of recruiment; or were in medically unstable conditions within 2 weeks of recruitment; currently taking anti-tuberculous or anti-fungal drugs; 3. test results show one of the following characteristics: alanine aminotransferase (ALT)/ aspartate amino transferase (AST) greater than10 times the upper limit of normal (ULN), total bilirubin (TB) greater than 2 times ULN, eGFR12.5Kpa; (3) APRI>2 (APRI Scoring formula: AST/ULN×100; PLT (10^9/L).

Design outcomes

Primary

MeasureTime frame
HIVRNA;HCVRNA;

Countries

China

Contacts

Public ContactWeiping Cai

Guangzhou Eighth People's Hospital

gz8hcwp@126.com+86 13808815909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026